Comparative Pharmacology
Head-to-head clinical analysis: DECLOMYCIN versus DOXYCYCLINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DECLOMYCIN versus DOXYCYCLINE.
DECLOMYCIN vs DOXYCYCLINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to the 30S ribosomal subunit, inhibiting aminoacyl-tRNA binding to the mRNA-ribosome complex, thereby blocking protein synthesis.
Doxycycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the attachment of aminoacyl-tRNA to the mRNA-ribosome complex. It also exhibits anti-inflammatory and anti-collagenase activities.
150 mg orally every 6 hours or 300 mg orally every 12 hours.
100 mg orally or intravenously every 12 hours on day 1, then 100 mg every 12 hours or 50 mg every 6 hours.
None Documented
None Documented
Terminal elimination half-life 10-17 hours; prolonged to 18-48 hours in renal impairment
Clinical Note
moderateMethoxsalen + Doxycycline
"The metabolism of Doxycycline can be decreased when combined with Methoxsalen."
Clinical Note
moderateCyclophosphamide + Doxycycline
"The metabolism of Doxycycline can be decreased when combined with Cyclophosphamide."
Clinical Note
moderatePaclitaxel + Doxycycline
"The metabolism of Doxycycline can be decreased when combined with Paclitaxel."
Clinical Note
moderateDocetaxel + Doxycycline
Terminal elimination half-life is 18–24 hours in patients with normal renal function; prolonged to 20–30 hours in renal impairment; allows once or twice daily dosing.
Renal: ~50% unchanged; biliary/fecal: ~40% as inactive metabolites; enterohepatic recycling occurs
Renal (40%) and fecal/biliary (60%); undergoes enterohepatic circulation; active drug and metabolites excreted in urine and feces.
Category C
Category D/X
Tetracycline Antibiotic
Tetracycline Antibiotic
"The metabolism of Doxycycline can be decreased when combined with Docetaxel."